
TLX Stock Forecast & Price Target
TLX Analyst Ratings
Bulls say
Telix Pharmaceuticals is supported by a still-healthy core commercial engine, with 3Q26 revenue of $245MM and Precision Medicine revenue of $201MM up 30% y/y, while management reiterated confidence in >25% Precision Medicine growth for FY26 and revenue still tracking toward the upper end of the $950-970MM range. The bullish case is strengthened by a widening catalyst set: Pixclara created its first U.S. commercial presence in neuro-oncology, BiPASS has completed enrollment with FDA support for an NDA pathway, and Zircaix resubmission is planned near-term, all of which broaden growth beyond Illuccix. The proposed $1.65B ITM acquisition is strategically compelling because it adds scaled Lu-177 and Ac-225 supply, a $273MM revenue business in 2025 with >40% manufacturing gross margins, and a potentially profitable therapeutic asset in ITM-11, improving vertical integration and long-term earnings power.
Bears say
Telix Pharmaceuticals is exposed to meaningful downside because its valuation hinges on a concentrated portfolio of clinical-stage programs that could fail in development or face regulatory setbacks. The company also depends heavily on Illuccix for revenue, so any inability to achieve sales estimates would directly weaken its fundamental outlook and pressure growth. With pipeline assets spanning urologic oncology, neuro-oncology, musculoskeletal oncology, and hematology, execution risk remains high, and disappointments in either commercialization or clinical progress could impair results.
This aggregate rating is based on analysts' research of Telix Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.
TLX Analyst Forecast & Price Prediction
Start investing in TLX
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Telix Pharmaceuticals Ltd (TLX) Forecast
TLX Analyst Forecast & Price Prediction
Start investing in TLX
Order type
Buy in
Order amount
Est. shares
0 shares